For research and educational purposes only. Not medical advice.
ARA-290 Reference
Educational, not medical advice reference for ARA-290: Recovery, Immune, Longevity; regulatory status, evidence posture, source review, and sche…
Reference summary
Preclinical studies report tissue-protective, anti-inflammatory, and neuropathic-pain signals; clinical programs remain investigational and indication-specific.
Regulatory and posture
- Categories
- Recovery, Immune, Longevity
- Aliases
- Cibinetide, pHBSP, Pyroglutamate helix B surface peptide
- Evidence posture
- translational - Investigational EPO-derived peptide. Human community use for neuropathy, inflammation, or longevity is not validated by an approved product or broad outcome program.
- Regulatory status
- No FDA-approved ARA-290 / cibinetide drug label. ClinicalTrials.gov lists investigational studies, including sarcoidosis-associated small-fiber neuropathy. It is not approved for neuropathy, autoimmune disease, longevity, or recovery use.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: ARA290 neuropathic-pain animal study
- ClinicalTrials.gov: ARA 290 / cibinetide sarcoidosis small-fiber-neuropathy study
- PubMed: ARA290 cardiac inflammation and healthspan rat study
Related tools
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.
- Protocol builder overview - Public overview of the Pro protocol builder.